75 results about "Nitrogenous base" patented technology

A compound of a general structure:wherein:B is selected from the group consisting of derivatives of naturally occurring nitrogenous bases having a C-H group at positions 5 or 8, and derivatives of nitrogenous base-analogs having a C-H group at positions 5 or 8;D is at least one derivatizing group, including hydrogen; andM is a maleimide derivative.

Energetic materials, such as nitrocellulose, TNT, RDX, and combinations thereof, optionally in combination with chemical warfare agents, such as mustard gas, Lewisite, Tabun, Sarin, Toman, VX, and combinations thereof, are destroyed when chemically reacted according to the method of the invention. The method comprises reacting the energetic materials and chemical warfare agents, of present, with solvated electrons which are preferably produced by dissolving an active metal such as sodium in a nitrogenous base such as anhydrous liquid ammonia.

A composition and method are provided for alleviating the dermatological signs of intrinsic and extrinsic aging. A topical formulation containing a cosmeceutically active base, wherein the formulation provides a pH in the range of about 8.0 to 13.0 at the skin surface, is applied to the skin in order to prevent or treat aging-related skin conditions such as wrinkles, dry skin, age spots, sun damage (particularly UV radiation-induced oxidative stress), blemishes, hyperpigmented skin, age spots, increased skin thickness, loss of skin elasticity and collagen content, dry skin, lentigines and melasmas. The cosmeceutically active base is either an inorganic base, such as an inorganic hydroxide, an inorganic oxide, or a metal salt of a weak acid, or an organic base, particularly a nitrogenous base such as may be selected from primary amines, secondary amines, tertiary amines, amides, oximes, nitrites, aromatic and non-aromatic nitrogen-containing heterocycles, urea, and mixtures thereof.

Compositions comprising an alkanesulfonic acid and an organic nitrogenous base, and related methods of use.

A modified nucleoside analogue having the formula (I): P-S-B-L-R where: P is a 5′ triphosphate or analogue or derivative thereof; S is a substituted or unsubstituted five- or six-membered sugar, sugar analogue or acyclo sugar analogue, but excluding a dideoxy-sugar, B is a substituted or unsubstituted nitrogenous base or base analogue or derivative thereof; L is a linker group; and R is a substituted or unsubstituted metallocene moiety or substituted or unsubstituted metal complex or substituted or unsubstituted redox-active organic moiety. The modified nucleoside is capable of enzymatic incorporation into a nucleotide chain and allows for redox labelling of nucleotides.

The present invention concerns oligonucleotides containing one or more modified nucleotides which increase the binding affinity of the oligonucleotides to target nucleic acids having a complementary nucleotide base sequence. These modified oligonucleotides hybridize to the target sequence at a faster rate than unmodified oligonucleotides having an identical nucleotide base sequence. Such modified oligonucleotides include oligonucleotides containing at least one 2′-O-methylribofuranosyl moiety joined to a nitrogenous base. Oligonucleotides can be modified in accordance with the present invention to preferentially bind RNA targets. The present invention also concerns methods of using these modified oligonucleotides and kits containing the same.

This invention deals with crystalline, nitrogen copolyester lubricant coating devices comprising sutures, wherein said lubricant comprises a triaxial copolyester chain with a central nitrogenous base or a copolyester with more than one carboxylic group ionically linked to a basic amino acid.

The invention relates to a polypeptide nano-micelle for treatment of cancers. The polypeptide in the invention can inhibit cancer metastasis; the polypeptide nano-micelle is formed by self-assembling of pegylated phosphatide (PEG-PE) and the polypeptide; and the pegylated phosphatide is a compound formed by combination of polyethylene glycol with nitrogenous bases on phosphatide molecules through covalent bonds. Specifically, the invention relates to a method for improving biostability of the polypeptide through PEG-PE micelles and provides a preparation method for the polypeptide-PEG-PE nano-micelle and application of the polypeptide-PEG-PE nano-micelle in inhibition of cancer metastasis. The nano-micelle formed by PEG-PE and the polypeptide has good stability in a salt solution, and presents the stronger characteristic of inhibiting migration and infiltration of cancer cells. The polypeptide-PEG-PE nano-micelle provided by the invention provides a feasible method and technology for cancer metastasis inhibition and cancer treatment.

Ionic liquids containing a cation with a potentially nucleophilic carbon atom bearing a relatively acidic hydrogen atom bonded to a potentially nucleophilic carbon atom, typically in the conjugated —NC(H)N— structure or a —NC(H)S— structure of imidazolium, imidazolidinium or thiazolium salts, can be capable of acting as sorbents for CO2 in cyclic separation processes. The ionic liquid may be used on its own, mixed with a solvent, preferably an aprotic, polar, non-aqueous solvent such as toluene, DMSO, NMP or sulfolane, or in conjunction with a non-nucleophilic nitrogenous base promoter compound having a pKa of at least 10.0 such as a carboxamidine or a guanidine.

The invention discloses a method for preparing a nitrogen-producing carbon molecular sieve, which comprises the following steps: a. material proportion; b. fine pulverizing; c. extruding and moulding; d. high-temperature nitrogenous-base carbonizing; e. and high-temperature nitrogenous-base pore-forming treatment. Since the material selection, the material proportioning, the process parameter combination and the like of the invention are repeatedly tested, compared, concluded and summarized by the applicant, although the production method is not changed greatly, the obtained nitrogen-producing carbon molecular sieve has very prominent effect and has superior performance in several aspects such as the concentration of the produced nitrogen, the nitrogen yield, the recovery rate, the compressive strength and the like.

The present invention concerns oligonucleotides containing one or more modified nucleotides which increase the binding affinity of the oligonucleotides to target nucleic acids having a complementary nucleotide base sequence. These modified oligonucleotides hybridize to the target sequence at a faster rate than unmodified oligonucleotides having an identical nucleotide base sequence. Such modified oligonucleotides include oligonucleotides containing at least one 2′-O-methylribofuranosyl moiety joined to a nitrogenous base. Oligonucleotides can be modified in accordance with the present invention to preferentially bind RNA targets. The present invention also concerns methods of using these modified oligonucleotides and kits containing the same.

The invention discloses a biology base air source and a flame retardant polyolefin compound formed by the biology base air source. The biology base air source is nitrogenous base subjected to surface treatment by a coupling agent, wherein the nitrogenous base includes A, G, T, C, U and A-T, G-C and A-U. The flame retardant polyolefin compound comprises polyolefin, a flame retardant, a synergist, a lubricant and an antioxidant; the a flame retardant is formed by mixing an acid source, a carbon source and the biology base air source. The flame retardant polyolefin compound has the following characteristics that the flame retardant effect is good; the addition quantity of the flame retardant is small; the efficiency is high; the cost is low; the advantages of good mechanical property and light weight of polyolefin are maintained; the product heat stability is good; the flame retardant and the synergist are matched with polyolefin processing and pyrolysis temperature; no decomposition or equipment corrosion exists in the processing process; the acid source, the carbon source and the air source achieve a synergistic effect; after the combustion, a compact expansion carbon layer is formed to protect a lower layer base body; the flame retardant performance of the compound is obviously improved; the compound can pass through UL94V-0 level; melting dripping resistant performance is realized.

A solvent system comprising an ionic Liquid formed from a relatively acidic component and a nitrogenous base for the removal of acid gases from mixed gas streams is provided. Also provided is a process for removing acid gases from mixed gas streams using the disclosed solvent system. The solvent system may be utilized within a gas processing system.

The process for making extra high voltage cable insulation is improved by using a composition comprising in weight percent based on the weight of the composition: (A) 95 to 99.9% of an ethylene-basedpolymer; (B) 0.2 to 2.5% peroxide; (C) 0.01 to 0.5% of a sulfur-containing first antioxidant having at least one -S(CH2)2CO2R group, wherein R is a C6 to C20 alkyl; (D) 0.001 to 0.009%) of a phosphorus-containing second antioxidant that does not contain a -S(CH2)2C02R group, wherein R is a C6 to C20 alkyl; (E) Optionally, an organic nitrogenous base; and (F) Optionally, a phenolic third antioxidant that does not contain a -S(CH2)2C02R group, wherein R is a C6 to C20 alkyl.

Disclosed in the present invention is micellar polypeptide vaccine having pegylated phospholipid as carrier. The vaccine can prevent or treat tumors or can be used as combination formulation with anti-cancer activity formulation. The micellar polypeptide vaccine is formed of self-assembling pegylated phospholipid (PEG-PE) and antigenic polypeptides, the pegylated phospholipid being compound formed of polyethylene glycol (hydrophilic blocks) covalently bonded to nitrogenous bases on phospholipid molecule (hydrophobic blocks). The particle diameter of the micellar vaccine is 10-100 nm, and the antigenic polypeptides carried therein are polypeptides of 5-100 amino acids. The micellar polypeptide vaccine may also contain immunoadjuvant.

Provided herein are methods and compositions for expression of a nucleic acid construct comprising nucleic acids encoding a) a recombinant polypeptide, and b) a prototrophy-restoring enzyme in a host cell that is auxotrophic for at least one metabolite. In various embodiments, the host cell is auxotrophic for a nitrogenous base compound or an amino acid. The invention involves introducing an analogue into the growth media for the host cell such that the analogue is incorporated into the recombinant polypeptide or a nucleic acid coding sequence thereof. In various embodiments, the compositions and methods disclosed herein result in improved recombinant protein expression compared to expression of recombinant protein in an antibiotic selection system, or compared to expression of the recombinant protein in an expression system that lacks a metabolite analogue.

This invention relates to an organic tungsten complex prepared by providing a strongly acidic tungsten precursor having pH≦2.5, and either reacting the tungsten precursor with a nitrogenous base to form a tungsten salt intermediate having a pH ranging from ≧5 to ≦8.5, and further reacting the tungsten salt intermediate with a fatty acid derivative of an alcohol, wherein the fatty acid derivative of an alcohol contains at least one free hydroxyl group; or reacting the tungsten precursor with a fatty acid derivative of an alcohol, wherein the fatty acid derivative of an alcohol contains at least one free hydroxyl group and a nitrogenous base. Further, this invention relates to lubricating compositions containing the inventive tungsten complexes.

A modified nucleotide, intended for the synthesis of long chain nucleic acids by enzymatic processes, comprising a ''natural'' nitrogenous base or a natural nitrogenous base analogue, a ribose or deoxyribose carbohydrate, and at least one phosphate group, characterized in that said nucleotide comprises at least one R group, termed the modifier group, carried by said nitrogenous base or analogue and / or by the oxygen in position 3' of the ribose or deoxyribose molecule, making it possible to block the polymerization of said nucleotide and / or to allow the interaction of said nucleotide with another molecule, such as a protein, during the nucleic acid synthesis, R comprising at least one functional terminal group.

The process for making extra high voltage cable insulation is improved by using a composition comprising in weight percent based on the weight of the composition: (A) 95 to 99.9% of an ethylene-based polymer; (B) 0.2 to 2.5% peroxide; (C) 0.01 NI to 0.5% of a sulfur-containing first antioxidant having at least one —S(CH2)2CO2R group, wherein R is a C6 to C20 alkyl; (D) 0.001 to 0.009%) of a phosphorus-containing second antioxidant that does not contain a —S(CH2)2C02R group, wherein R is a C6 to C20 alkyl; (E) Optionally, an organic nitrogenous base; and (F) Optionally, a phenolic third antioxidant that does not contain a —S(CH2)2C02R group, wherein R is a C6 to C20 alkyl.

The present invention concerns oligonucleotides containing one or more modified nucleotides which increase the binding affinity of the oligonucleotides to target nucleic acids having a complementary nucleotide base sequence. These modified oligonucleotides hybridize to the target sequence at a faster rate than unmodified oligonucleotides having an identical nucleotide base sequence. Such modified oligonucleotides include oligonucleotides containing at least one 2′-O-methylribofuranosyl moiety joined to a nitrogenous base. Oligonucleotides can be modified in accordance with the present invention to preferentially bind RNA targets. The present invention also concerns methods of using these modified oligonucleotides and kits containing the same.

Methods, formulations, and drug delivery systems are provided for enhancing the flux of a transdermally administered hydrophilic drug using a basic permeation enhancer composition. The enhancer composition contains an inorganic hydroxide and a weaker, nitrogenous base, wherein the bases are selected such that a 0.1M aqueous solution of the nitrogenous base has a pH that is about 1.0 to about 6.5 lower than the pH of a 0.1M aqueous solution of the inorganic hydroxide. Additionally, the molar ratio of the nitrogenous base to the inorganic hydroxide in the enhancer composition is in the range of about 0.5n:1 to about 20n:1, where n is the number of hydroxide ions per molecule of the inorganic hydroxide.

Methods, formulations, and drug delivery systems are provided for enhancing the flux of a transdermally administered hydrophilic drug using a basic permeation enhancer composition. The enhancer composition contains an inorganic hydroxide and a weaker, nitrogenous base, wherein the bases are selected such that a 0.1M aqueous solution of the nitrogenous base has a pH that is about 1.0 to about 6.5 lower than the pH of a 0.1M aqueous solution of the inorganic hydroxide. Additionally, the molar ratio of the nitrogenous base to the inorganic hydroxide in the enhancer composition is in the range of about 0.5n:1 to about 20n:1, where n is the number of hydroxide ions per molecule of the inorganic hydroxide.

Tetrafluoroboric acid and an organic nitrogenous base, related compounds and compositions, as can be used in conjunction with various methods of cleaning and / or the treatment of substrate surfaces.

The present invention concerns oligonucleotides containing one or more modified nucleotides which increase the binding affinity of the oligonucleotides to target nucleic acids having a complementary nucleotide base sequence. These modified oligonucleotides hybridize to the target sequence at a faster rate than unmodified oligonucleotides having an identical nucleotide base sequence. Such modified oligonucleotides include oligonucleotides containing at least one 2′-O-methylribofuranosyl moiety joined to a nitrogenous base. Oligonucleotides can be modified in accordance with the present invention to preferentially bind RNA targets. The present invention also concerns methods of using these modified oligonucleotides and kits containing the same.

Provided herein are methods and compositions for expression of a nucleic acid construct comprising nucleic acids encoding a) a recombinant polypeptide, and b) a prototrophy-restoring enzyme in a host cell that is auxotrophic for at least one metabolite. In various embodiments, the host cell is auxotrophic for a nitrogenous base compound or an amino acid. The invention involves introducing an analogue into the growth media for the host cell such that the analogue is incorporated into the recombinant polypeptide or a nucleic acid coding sequence thereof. In various embodiments, the compositions and methods disclosed herein result in improved recombinant protein expression compared to expression of recombinant protein in an antibiotic selection system, or compared to expression of the recombinant protein in an expression system that lacks a metabolite analogue.